Evidence map›Paper›PMID 30446622›Full record

ArticleThe Journal of biological chemistry2019

Domain analysis of PNKP-XRCC1 interactions: Influence of genetic variants of XRCC1.

Rajam S Mani, Inbal Mermershtain, Ismail Abdou, Mesfin Fanta, Michael J Hendzel, J N Mark Glover, Michael Weinfeld

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Fructose-2,6-bisphosphate restores DNA repair activity of PNKP and ameliorates neurodegenerative symptoms in Huntington's disease.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rajam S ManiFrom the Department of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2 and.
Inbal Mermershtainthe Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada.
Ismail AbdouFrom the Department of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2 and.
Mesfin FantaFrom the Department of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2 and.
Michael J HendzelFrom the Department of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2 and.
J N Mark Gloverthe Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada.
Michael WeinfeldFrom the Department of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2 and mweinfel@ualberta.ca.ORCID 0000-0002-8773-1425
University of Alberta · CA

Funding

Transcription-Coupled & Replication-Associated Excision RepairP01CA092584 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI John A. Tainer · 2001 to 2026
$89.6M
CIHR MOP15385NCI NIH HHS P01 CA092584
6 · The paper itself

Abstract

Polynucleotide kinase/phosphatase (PNKP) and X-ray repair cross-complementing 1 (XRCC1) are key proteins in the single-strand DNA break repair pathway. Phosphorylated XRCC1 stimulates PNKP by binding to its forkhead-associated (FHA) domain, whereas nonphosphorylated XRCC1 stimulates PNKP by interacting with the PNKP catalytic domain. Here, we have further studied the interactions between these two proteins, including two variants of XRCC1 (R194W and R280H) arising from single-nucleotide polymorphisms (SNPs) that have been associated with elevated cancer risk in some reports. We observed that interaction of the PNKP FHA domain with phosphorylated XRCC1 extends beyond the immediate, well-characterized phosphorylated region of XRCC1 (residues 515-526). We also found that an XRCC1 fragment, comprising residues 166-436, binds tightly to PNKP and DNA and efficiently activates PNKP's kinase activity. However, interaction of either of the SNP-derived variants of this fragment with PNKP was considerably weaker, and their stimulation of PNKP was severely reduced, although they still could bind DNA effectively. Laser microirradiation revealed reduced recruitment of PNKP to damaged DNA in cells expressing either XRCC1 variant compared with PNKP recruitment in cells expressing WT XRCC1 even though WT and variant XRCC1s were equally efficient at localizing to the damaged DNA. These findings suggest that the elevated risk of cancer associated with these XRCC1 SNPs reported in some studies may be due in part to the reduced ability of these XRCC1 variants to recruit PNKP to damaged DNA.

Indexed as

Polymorphism, Single NucleotideProtein Interaction Domains and MotifsAnimalsCHO CellsCricetulusDNA DamageDNA Repair EnzymesPhosphotransferases (Alcohol Group Acceptor)Protein Interaction MapsX-ray Repair Cross Complementing Protein 1DNA Repair EnzymesPhosphotransferases (Alcohol Group Acceptor)PNKP protein, humanX-ray Repair Cross Complementing Protein 1XRCC1 protein, humancircular dichroism (CD)DNA repairfluorescence spectroscopylaser-microirradiationpolynucleotide kinase/phosphataseprotein-nucleic acid interactionprotein-protein interactionsingle-nucleotide polymorphism (SNP)X-ray repair cross-complementingXRCC1

Identifiers

PMID30446622
PMCPMC6333889
OpenAlexW2900741157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.